Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.

Lee RS, Zhang L, Berger A, Lawrence MG, Song J, Niranjan B, Davies RG, Lister NL, Sandhu SK, Rubin MA, Risbridger GP, Taylor RA, Rickman DS, Horvath LG, Daly RJ.

Neoplasia. 2019 Apr;21(4):389-400. doi: 10.1016/j.neo.2019.02.005. Epub 2019 Mar 20.

2.

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H.

Sci Transl Med. 2019 Mar 20;11(484). pii: eaav0891. doi: 10.1126/scitranslmed.aav0891.

3.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
4.

The Expanding World of N-MYC-Driven Tumors.

Rickman DS, Schulte JH, Eilers M.

Cancer Discov. 2018 Feb;8(2):150-163. doi: 10.1158/2159-8290.CD-17-0273. Epub 2018 Jan 22. Review.

5.

Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle.

Büchel G, Carstensen A, Mak KY, Roeschert I, Leen E, Sumara O, Hofstetter J, Herold S, Kalb J, Baluapuri A, Poon E, Kwok C, Chesler L, Maric HM, Rickman DS, Wolf E, Bayliss R, Walz S, Eilers M.

Cell Rep. 2017 Dec 19;21(12):3483-3497. doi: 10.1016/j.celrep.2017.11.090.

6.

A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA, Rickman DS.

Cold Spring Harb Mol Case Stud. 2017 Sep;3(5). pii: a001487. doi: 10.1101/mcs.a001487. Epub 2017 May 3.

7.

Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.

Dhingra P, Martinez-Fundichely A, Berger A, Huang FW, Forbes AN, Liu EM, Liu D, Sboner A, Tamayo P, Rickman DS, Rubin MA, Khurana E.

Genome Biol. 2017 Jul 27;18(1):141. doi: 10.1186/s13059-017-1266-3.

8.

Biology and evolution of poorly differentiated neuroendocrine tumors.

Rickman DS, Beltran H, Demichelis F, Rubin MA.

Nat Med. 2017 Jun 6;23(6):1-10. doi: 10.1038/nm.4341.

PMID:
28586335
9.

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS.

Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005.

10.

A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.

Gayvert KM, Dardenne E, Cheung C, Boland MR, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS, Elemento O.

Cell Rep. 2016 Jun 14;15(11):2348-56. doi: 10.1016/j.celrep.2016.05.037. Epub 2016 Jun 2.

11.

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park K, Banfelder J, Prandi D, Madhukar N, Zhang T, Padilla J, Greco N, McNary TJ, Herrscher E, Wilkes D, MacDonald TY, Xue H, Vacic V, Emde AK, Oschwald D, Tan AY, Chen Z, Collins C, Gleave ME, Wang Y, Chakravarty D, Schiffman M, Kim R, Campagne F, Robinson BD, Nanus DM, Tagawa ST, Xiang JZ, Smogorzewska A, Demichelis F, Rickman DS, Sboner A, Elemento O, Rubin MA.

JAMA Oncol. 2015 Jul;1(4):466-74. doi: 10.1001/jamaoncol.2015.1313.

12.

ERG induces taxane resistance in castration-resistant prostate cancer.

Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS.

Nat Commun. 2014 Nov 25;5:5548. doi: 10.1038/ncomms6548.

13.

Environmental Public Health Applications Using Remotely Sensed Data.

Al-Hamdan MZ, Crosson WL, Economou SA, Estes MG Jr, Estes SM, Hemmings SN, Kent ST, Puckett M, Quattrochi DA, Rickman DL, Wade GM, McClure LA.

Geocarto Int. 2014 Jan 1;29(1):85-98.

14.

Aggressive variants of castration-resistant prostate cancer.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA.

Clin Cancer Res. 2014 Jun 1;20(11):2846-50. doi: 10.1158/1078-0432.CCR-13-3309. Epub 2014 Apr 11. Review.

15.

Prevention of neuromusculoskeletal frailty in slow-aging ames dwarf mice: longitudinal investigation of interaction of longevity genes and caloric restriction.

Arum O, Rasche ZA, Rickman DJ, Bartke A.

PLoS One. 2013 Oct 14;8(10):e72255. doi: 10.1371/journal.pone.0072255. eCollection 2013.

16.

The slow-aging growth hormone receptor/binding protein gene-disrupted (GHR-KO) mouse is protected from aging-resultant neuromusculoskeletal frailty.

Arum O, Rickman DJ, Kopchick JJ, Bartke A.

Age (Dordr). 2014 Feb;36(1):117-27. doi: 10.1007/s11357-013-9551-x. Epub 2013 Jul 4.

17.

CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.

Bisig B, de Reyniès A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, Delsol G, Lamant L, Gaulard P, de Leval L.

Haematologica. 2013 Aug;98(8):1250-8. doi: 10.3324/haematol.2012.081935. Epub 2013 May 28.

18.

Oncogenic transcription factors as master regulators of chromatin topology: a new role for ERG in prostate cancer.

Elemento O, Rubin MA, Rickman DS.

Cell Cycle. 2012 Sep 15;11(18):3380-3. doi: 10.4161/cc.21401. Epub 2012 Aug 23.

19.

Oncogene-mediated alterations in chromatin conformation.

Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V, Demichelis F, Melnick AM, Elemento O, Rubin MA.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9083-8. doi: 10.1073/pnas.1112570109. Epub 2012 May 21.

20.

Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.

Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ Jr, Abraham C, Banerjee S, Leung RA, Tewari AK, Terry S, Shevchuk MM, Rickman DS, Rubin MA; Weill Cornell Medical College.

Diagn Mol Pathol. 2012 Jun;21(2):61-8. doi: 10.1097/PDM.0b013e31823b6da6.

21.

Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JY, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnaiyan AM, Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT, Scherr DS, Sanda MA, Bartsch G, Lee C, Klocker H, Rubin MA.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6686-91. doi: 10.1073/pnas.1117405109. Epub 2012 Apr 10.

22.

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA.

Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130.

23.

Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies.

Dev H, Rickman D, Sooriakumaran P, Srivastava A, Grover S, Leung R, Kim R, Kitabayashi N, Esqueva R, Park K, Padilla J, Rubin M, Tewari A.

J Transl Med. 2011 Jul 26;9:121. doi: 10.1186/1479-5876-9-121.

24.

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.

Urol Oncol. 2013 Jul;31(5):566-71. doi: 10.1016/j.urolonc.2011.04.001. Epub 2011 May 19.

25.

ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.

Rickman DS, Chen YB, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F.

Neoplasia. 2010 Dec;12(12):1031-40.

26.

Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin PC, Svensson MA, Kitabayashi N, Moss BJ, MacDonald TY, Cao X, Barrette T, Tewari AK, Chee MS, Chinnaiyan AM, Rickman DS, Demichelis F, Gerstein MB, Rubin MA.

Genome Res. 2011 Jan;21(1):56-67. doi: 10.1101/gr.110684.110. Epub 2010 Oct 29.

27.

An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.

Ducray F, de Reyniès A, Chinot O, Idbaih A, Figarella-Branger D, Colin C, Karayan-Tapon L, Chneiweiss H, Wager M, Vallette F, Marie Y, Rickman D, Thomas E, Delattre JY, Honnorat J, Sanson M, Berger F.

Mol Cancer. 2010 Sep 7;9:234. doi: 10.1186/1476-4598-9-234.

28.

ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F, Rickman DS, Rubin MA.

Urology. 2010 Apr;75(4):762-7. doi: 10.1016/j.urology.2009.10.010.

29.

Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma.

Jung AC, Briolat J, Millon R, de Reyniès A, Rickman D, Thomas E, Abecassis J, Clavel C, Wasylyk B.

Int J Cancer. 2010 Apr 15;126(8):1882-1894. doi: 10.1002/ijc.24911.

30.

In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.

Wagner PL, Perner S, Rickman DS, LaFargue CJ, Kitabayashi N, Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA.

Am J Clin Pathol. 2009 Oct;132(4):500-5. doi: 10.1309/AJCPF10ZUNSOLIFG.

PMID:
19762526
31.

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

Neoplasia. 2009 Aug;11(8):804-11.

32.

Methods for characterizing fine particulate matter using ground observations and remotely sensed data: potential use for environmental public health surveillance.

Al-Hamdan MZ, Crosson WL, Limaye AS, Rickman DL, Quattrochi DA, Estes MG Jr, Qualters JR, Sinclair AH, Tolsma DD, Adeniyi KA, Niskar AS.

J Air Waste Manag Assoc. 2009 Jul;59(7):865-81.

PMID:
19645271
33.

WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?

Corbin M, de Reyniès A, Rickman DS, Berrebi D, Boccon-Gibod L, Cohen-Gogo S, Fabre M, Jaubert F, Faussillon M, Yilmaz F, Sarnacki S, Landman-Parker J, Patte C, Schleiermacher G, Antignac C, Jeanpierre C.

Genes Chromosomes Cancer. 2009 Sep;48(9):816-27. doi: 10.1002/gcc.20686.

PMID:
19530245
34.

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA.

Cancer Res. 2009 Apr 1;69(7):2734-8. doi: 10.1158/0008-5472.CAN-08-4926. Epub 2009 Mar 17.

35.

Distinct genomic aberrations associated with ERG rearranged prostate cancer.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A, Svensson MA, Rickman DS, Urban A, Snyder M, Meyerson M, Lee C, Gerstein MB, Kuefer R, Rubin MA.

Genes Chromosomes Cancer. 2009 Apr;48(4):366-80. doi: 10.1002/gcc.20647.

36.

Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival.

de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J.

J Clin Oncol. 2009 Mar 1;27(7):1108-15. doi: 10.1200/JCO.2008.18.5678. Epub 2009 Jan 12.

PMID:
19139432
37.

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.

Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, Pontoglio M, Strick-Marchand H, Levillayer F, Nouet Y, Rickman D, Gauthier F, Branchereau S, Brugières L, Laithier V, Bouvier R, Boman F, Basso G, Michiels JF, Hofman P, Arbez-Gindre F, Jouan H, Rousselet-Chapeau MC, Berrebi D, Marcellin L, Plenat F, Zachar D, Joubert M, Selves J, Pasquier D, Bioulac-Sage P, Grotzer M, Childs M, Fabre M, Buendia MA.

Cancer Cell. 2008 Dec 9;14(6):471-84. doi: 10.1016/j.ccr.2008.11.002.

38.

Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays.

Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, Abecassis J, Wasylyk B.

Oncogene. 2008 Nov 20;27(51):6607-22. doi: 10.1038/onc.2008.251. Epub 2008 Aug 4.

PMID:
18679425
39.

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K; Groupe d'Etude des Lymphomes de l'Adulte.

Leukemia. 2008 Oct;22(10):1917-24. doi: 10.1038/leu.2008.188. Epub 2008 Jul 10.

40.

EML4-ALK fusion lung cancer: a rare acquired event.

Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA.

Neoplasia. 2008 Mar;10(3):298-302.

41.

Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate.

Decaens T, Godard C, de Reyniès A, Rickman DS, Tronche F, Couty JP, Perret C, Colnot S.

Hepatology. 2008 Jan;47(1):247-58.

PMID:
18038450
42.

Oxidative stress-induced expression and modulation of Phosphatase of Regenerating Liver-1 (PRL-1) in mammalian retina.

Yu L, Kelly U, Ebright JN, Malek G, Saloupis P, Rickman DW, McKay BS, Arshavsky VY, Bowes Rickman C.

Biochim Biophys Acta. 2007 Sep;1773(9):1473-82. Epub 2007 Jun 26.

43.

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PLoS Med. 2007 Mar;4(3):e90.

44.

The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.

de Leval L, Rickman DS, Thielen C, Reynies Ad, Huang YL, Delsol G, Lamant L, Leroy K, Brière J, Molina T, Berger F, Gisselbrecht C, Xerri L, Gaulard P.

Blood. 2007 Jun 1;109(11):4952-63. Epub 2007 Feb 6.

45.

Initial observations of key features of age-related macular degeneration in APOE targeted replacement mice.

Malek G, Mace B, Saloupis P, Schmechel D, Rickman D, Sullivan P, Rickman CB.

Adv Exp Med Biol. 2006;572:109-17. No abstract available.

PMID:
17249563
46.

Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia.

dos Santos NR, Rickman DS, de Reynies A, Cormier F, Williame M, Blanchard C, Stern MH, Ghysdael J.

Blood. 2007 May 1;109(9):3972-81. Epub 2006 Dec 27.

47.

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J.

Hepatology. 2007 Jan;45(1):42-52.

PMID:
17187432
48.

Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice.

Chute JP, Muramoto GG, Salter AB, Meadows SK, Rickman DW, Chen B, Himburg HA, Chao NJ.

Blood. 2007 Mar 15;109(6):2365-72. Epub 2006 Nov 9.

49.

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.

Lamant L, de Reyniès A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugières L, Gaulard P, Espinos E, Delsol G.

Blood. 2007 Mar 1;109(5):2156-64. Epub 2006 Oct 31.

50.

Apc tumor suppressor gene is the "zonation-keeper" of mouse liver.

Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S.

Dev Cell. 2006 Jun;10(6):759-70.

Supplemental Content

Loading ...
Support Center